Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality
worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC …

Hepatocellular carcinoma (HCC) is the most frequent liver cancer with high lethality and low
five-year survival rates leading to a substantial worldwide burden for healthcare systems …

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading
cause of cancer-related death worldwide. It is highly refractory to most systemic therapies …

Hepatocellular carcinoma (HCC) is a significant cause of cancer-related mortality owing to
resistance to traditional treatments and tumor recurrence after therapy, which leads to poor …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Computed tomography (CT) and magnetic resonance (MR) imaging play critical roles in the
diagnosis and staging of hepatocellular carcinoma (HCC). The first article of this two-part …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Several highly effective, interferon‐free, direct‐acting antiviral (DAA)‐based regimens are
available for the treatment of chronic hepatitis C virus (HCV) infection. Despite impressive …

Background No effective systemic therapy exists for patients with advanced hepatocellular
carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the …